Noxopharm Limited (ASX:NOX) has disclosed a change in the relevant interests of director Peter Marks, following the issue of 372,105 ordinary shares to Shanti Capital Pty Ltd, an entity controlled by Marks, in lieu of directors' fees on 20 November 2026.

Key Points

  • 372,105 fully paid ordinary shares were issued to Shanti Capital Pty Ltd, an entity controlled by director Peter Marks, on 20 November 2026.
  • The shares were issued at $0.0907 per fully paid ordinary share as non-cash consideration in lieu of directors' fees.
  • The issuance followed shareholder approval granted on 17 November 2026.
  • Shanti Capital Pty Ltd held 900,000 ordinary shares prior to the change, increasing to 1,272,105 ordinary shares after the transaction.

Share Issuance in Lieu of Directors' Fees

According to the filing, 372,105 fully paid ordinary shares were issued to Shanti Capital Pty Ltd on 20 November 2026, at a price of $0.0907 per share as non-cash consideration. The shares were issued in lieu of directors' fees following shareholder approval obtained at a meeting held on 17 November 2026. The interest disclosed is indirect, with Shanti Capital Pty Ltd identified as the registered holder and as an entity controlled by director Peter Marks. No securities were disposed of in connection with this transaction.

Peter Marks' Updated Indirect Shareholding in Noxopharm

Prior to the change, Shanti Capital Pty Ltd held 900,000 ordinary shares in Noxopharm Limited. Following the issue of 372,105 additional shares, the total holding of Shanti Capital Pty Ltd increased to 1,272,105 ordinary shares. The filing states the interest is indirect in nature, arising through Shanti Capital Pty Ltd, an entity controlled by Peter Marks. The previous director's interest notice for Peter Marks was dated 1 March 2021, according to the filing.

Closed Period and Contract Interest Disclosures

The filing states that the interests in securities detailed in the notice were not traded during a closed period where prior written clearance was required. No changes to the director's interests in contracts were reported, with all relevant fields under Part 2 of the notice recorded as not applicable. The disclosure was made by Noxopharm Limited under ASX listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act, with ABN 50 608 966 123 recorded for the entity.